DOK5 as a Prognostic Biomarker of Gastric Cancer Immunoinvasion: A Bioinformatics Analysis

Table 1

Kaplan-Meier plotter was used to analyze the correlation between DOK5 mRNA expression and different clinicopathological factors in gastric cancer.

Clinicopathological factors	Overall survival			Progression-free survival
		Hazard ratio	value		Hazard ratio	value
Sex
Female	244	1.47 (1.03-2.08)		201	1.46 (1-2.13)	0.051
Male	566	1.28 (1.03-1.59)		437	1.08 (0.85-1.37)	0.55
Stage
1	69	0.63 (0.23-1.71)	0.36	60	0.66 (0.22-2)	0.46
2	145	1.74 (0.93-3.25)	0.077	131	1.5 (0.8-2.79)	0.2
3	319	1.54 (1.15-2.05)		186	1.77 (1.21-2.58)
4	152	1.5 (1.02-2.21)		141	1.41 (0.96-2.07)	0.083
Stage T
1	14	—	—	14	—	—
2	253	1.87 (1.21-2.9)		239	1.66 (1.09-2.54)
3	208	1.27 (0.9-1.8)	0.17	204	1.22 (0.87-1.7)	0.24
4	39	1.59 (0.69-3.62)	0.27	39	2.49 (1.14-5.47)
Stage N
0	76	1.04 (0.44-2.47)	0.92	72	1.21 (0.52-2.8)	0.66
1	232	2.43 (1.57-3.75)		222	2.49 (1.64-3.79)
2	129	1.78 (1.13-2.81)		125	1.56 (1.01-2.41)
3	76	1.88 (1.1-3.22)		76	1.59 (0.93-2.72)	0.085
1+2+3	437	1.97 (1.51-2.58)		423	1.9 (1.47-2.47)
Stage M
0	459	1.8 (1.36-2.39)		443	1.71 (1.3-2.24)
1	58	1.76 (0.98-3.17)	0.0573	56	1.4 (0.77-2.53)	0.27
Lauren classification
Intestinal	336	1.95 (1.41-2.7)		263	1.73 (1.2-2.47)
Diffuse	248	1.63 (1.16-2.3)		231	1.67 (1.18-2.37)
Mixed	33	2.02 (0.72-5.71)	0.1743	28	1.67 (0.6-4.68)	0.32
Differentiation
Poorly differentiated	165	1.19 (0.8-1.78)	0.39	121	1.35 (0.85-2.15)	0.2
Moderately differentiated	67	1.41 (0.73-2.69)	0.3	67	1.58 (0.85-2.96)	0.15
Well differentiated	32	2.45 (1.01-5.95)		5	—	—
HER2 status
HER2 negative	532	1.47 (1.17-1.85)		408	1.35 (1.04-1.75)
HER2 positive	343	1.16 (0.9-1.51)	0.26	232	1.24 (0.9-1.71)	0.19

, , and .